Carl Y Zhang1, Jennifer L Vande Voort2, Deniz Yuruk2, Jeffrey A Mills3, Graham J Emslie4,5, Betsy D Kennard4, Taryn Mayes4, Madhukar Trivedi4, William V Bobo6, Jeffrey R Strawn7, Arjun P Athreya1, Paul E Croarkin2. 1. Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA. 2. Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA. 3. Department of Economics, University of Cincinnati, Cincinnati, Ohio, USA. 4. Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 5. Children's Health, Children's Medical Center, Dallas, Texas, USA. 6. Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, Florida, USA. 7. Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, Ohio, USA.
Abstract
Introduction: The Clinical Global Impressions-Improvement (CGI-I) scale is widely used in clinical research to assess symptoms and functioning in the context of treatment. The correlates of the CGI-I with efficacy scales for adolescent major depressive disorder are poorly understood. This study focused on benchmarking CGI-I scores with changes in the Children's Depression Rating Scale-Revised (CDRS-R) and the Quick Inventory of Depressive Symptomatology-Adolescent (17-item) Self-Report (QIDS-A17-SR). Methods: We examined three datasets with the clinician-rated CDRS-R to ascertain equivalent percent changes in total scores and CGI-I ratings. Exploratory analyses examined corresponding percentage changes in the QIDS-A17-SR and the CGI-I ratings. The CGI-I was the reference scale for nonparametric equipercentile linking with the Equate package in R. Results: CGI-I scores of 1 mapped to ≥78%-95% change in CDRS-R scores at 4-6 weeks across three datasets. CGI-I scores of 2 mapped to 56%-94% change in CDRS-R scores at 4-6 weeks across three studies. CGI-I scores of 3 mapped to 30%-68% changes in CDRS-R scores at 4-6 weeks across three studies. CGI-I scores of 4 mapped to a range of 29%-44% at 4-6 weeks across three studies. There was no significant difference (p ≥ 0.6) between treatment groups in both the Treatment of Adolescents with Depression and Treatment of Resistant Depression in Adolescents studies, for each CGI-I score ( = 1, or = 2 or = 3, or ≥4), associated mapping of total depression severity score, or associated percent change from baseline for corresponding follow-up visits. There was no significant sex difference (p > 0.2) in CGI-I linkages to CDRS-R total or percentage changes. Conclusions: These findings establish clear relationships among CGI-I scores and the CDRS-R and the QIDS-A17-SR. These benchmarks have utility for clinical trial study design, inter-rater reliability training, and clinical implementation.
Introduction: The Clinical Global Impressions-Improvement (CGI-I) scale is widely used in clinical research to assess symptoms and functioning in the context of treatment. The correlates of the CGI-I with efficacy scales for adolescent major depressive disorder are poorly understood. This study focused on benchmarking CGI-I scores with changes in the Children's Depression Rating Scale-Revised (CDRS-R) and the Quick Inventory of Depressive Symptomatology-Adolescent (17-item) Self-Report (QIDS-A17-SR). Methods: We examined three datasets with the clinician-rated CDRS-R to ascertain equivalent percent changes in total scores and CGI-I ratings. Exploratory analyses examined corresponding percentage changes in the QIDS-A17-SR and the CGI-I ratings. The CGI-I was the reference scale for nonparametric equipercentile linking with the Equate package in R. Results: CGI-I scores of 1 mapped to ≥78%-95% change in CDRS-R scores at 4-6 weeks across three datasets. CGI-I scores of 2 mapped to 56%-94% change in CDRS-R scores at 4-6 weeks across three studies. CGI-I scores of 3 mapped to 30%-68% changes in CDRS-R scores at 4-6 weeks across three studies. CGI-I scores of 4 mapped to a range of 29%-44% at 4-6 weeks across three studies. There was no significant difference (p ≥ 0.6) between treatment groups in both the Treatment of Adolescents with Depression and Treatment of Resistant Depression in Adolescents studies, for each CGI-I score ( = 1, or = 2 or = 3, or ≥4), associated mapping of total depression severity score, or associated percent change from baseline for corresponding follow-up visits. There was no significant sex difference (p > 0.2) in CGI-I linkages to CDRS-R total or percentage changes. Conclusions: These findings establish clear relationships among CGI-I scores and the CDRS-R and the QIDS-A17-SR. These benchmarks have utility for clinical trial study design, inter-rater reliability training, and clinical implementation.
Authors: Laura P Richardson; Elizabeth McCauley; David C Grossman; Carolyn A McCarty; Julie Richards; Joan E Russo; Carol Rockhill; Wayne Katon Journal: Pediatrics Date: 2010-11-01 Impact factor: 7.124
Authors: Ira H Bernstein; A John Rush; Madhukar H Trivedi; Carroll W Hughes; Laurie Macleod; Bradley P Witte; Shailesh Jain; Taryn L Mayes; Graham J Emslie Journal: Int J Methods Psychiatr Res Date: 2010-12 Impact factor: 4.035
Authors: Nathan D Shippee; Angela Mattson; RoxAnne Brennan; John Huxsahl; Marcie L Billings; Mark D Williams Journal: Psychiatr Serv Date: 2018-02-15 Impact factor: 3.084
Authors: Ethan A Poweleit; Stacey L Aldrich; Lisa J Martin; David Hahn; Jeffrey R Strawn; Laura B Ramsey Journal: J Child Adolesc Psychopharmacol Date: 2019-05-08 Impact factor: 2.576
Authors: Aiswarya Laks Nandakumar; Jennifer L Vande Voort; Paul A Nakonezny; Scott S Orth; Magdalena Romanowicz; Ayse Irem Sonmez; Jessica A Ward; Sandra J Rackley; John E Huxsahl; Paul E Croarkin Journal: J Child Adolesc Psychopharmacol Date: 2018-11-02 Impact factor: 2.576
Authors: Peter J Na; Satyanarayana R Yaramala; Jihoon A Kim; Hyelee Kim; Fernando S Goes; Peter P Zandi; Jennifer L Vande Voort; Bruce Sutor; Paul Croarkin; William V Bobo Journal: J Affect Disord Date: 2018-02-17 Impact factor: 4.839
Authors: John March; Susan Silva; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Benedetto Vitiello; Joanne Severe; Karyn Riedal; Marguerita Goldman; Norah Feeny; Robert Findling; Sheridan Stull; Susan Baab; Elizabeth B Weller; Michele Robbins; Ronald A Weller; Naushad Jessani; Bruce Waslick; Michael Sweeney; Randi Dublin; John Walkup; Golda Ginsburg; Elizabeth Kastelic; Hyung Koo; Christopher Kratochvil; Diane May; Randy LaGrone; Brigette Vaughan; Anne Marie Albano; Glenn S Hirsch; Elizabeth Podniesinki; Angela Chu; Mark Reincecke; Bennett Leventhal; Gregory Rogers; Rachel Jacobs; Sanjeev Pathak; Jennifer Wells; Sarah A Lavanier; Arman Danielyan; Paul Rohde; Anne Simons; James Grimm; Stephanie Frank; Graham Emslie; Beth Kennard; Carroll Hughes; Taryn L Mayes; David Rosenberg; Nili Benazon; Michael Butkus; Marla Bartoi Journal: Am J Psychiatry Date: 2009-09-01 Impact factor: 18.112